Suppr超能文献

相似文献

1
Dysfunctional T cell metabolism in the tumor microenvironment.
Cytokine Growth Factor Rev. 2017 Jun;35:7-14. doi: 10.1016/j.cytogfr.2017.04.003. Epub 2017 Apr 23.
2
Emerging concepts of T cell metabolism as a target of immunotherapy.
Nat Immunol. 2016 Apr;17(4):364-8. doi: 10.1038/ni.3415.
3
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism.
Cytokine Growth Factor Rev. 2017 Jun;35:15-25. doi: 10.1016/j.cytogfr.2017.04.001. Epub 2017 Apr 11.
4
Editorial: Metabolism of Cancer Cells and Immune Cells in the Tumor Microenvironment.
Front Immunol. 2018 Dec 21;9:3080. doi: 10.3389/fimmu.2018.03080. eCollection 2018.
6
Immunometabolism: A new target for improving cancer immunotherapy.
Adv Cancer Res. 2019;143:195-253. doi: 10.1016/bs.acr.2019.03.004. Epub 2019 Apr 17.
7
Metabolic Barriers to T Cell Function in Tumors.
J Immunol. 2018 Jan 15;200(2):400-407. doi: 10.4049/jimmunol.1701041.
8
Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Clin Cancer Res. 2018 Jun 1;24(11):2473-2481. doi: 10.1158/1078-0432.CCR-17-0894. Epub 2018 Jan 31.
9
Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 24;22(19):10268. doi: 10.3390/ijms221910268.
10
Control of T Cell Metabolism by Cytokines and Hormones.
Front Immunol. 2021 Apr 13;12:653605. doi: 10.3389/fimmu.2021.653605. eCollection 2021.

引用本文的文献

2
Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.
Acta Pharm Sin B. 2025 Jun;15(6):2845-2866. doi: 10.1016/j.apsb.2025.04.002. Epub 2025 Apr 4.
3
Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies.
Cancers (Basel). 2025 Apr 23;17(9):1408. doi: 10.3390/cancers17091408.
4
New insights into T cell metabolism in liver cancer: from mechanism to therapy.
Cell Death Discov. 2025 Mar 23;11(1):118. doi: 10.1038/s41420-025-02397-w.
6
Cancer cell targeting by CAR-T cells: A matter of stemness.
Front Mol Med. 2022 Dec 13;2:1055028. doi: 10.3389/fmmed.2022.1055028. eCollection 2022.
7
Metabolic adaptations in prostate cancer.
Br J Cancer. 2024 Nov;131(8):1250-1262. doi: 10.1038/s41416-024-02762-z. Epub 2024 Jul 5.
10
STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment.
Mol Cell Biochem. 2024 Jul;479(7):1697-1705. doi: 10.1007/s11010-024-04970-w. Epub 2024 Apr 9.

本文引用的文献

1
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity.
JCI Insight. 2017 Feb 9;2(3):e89160. doi: 10.1172/jci.insight.89160.
3
Differential PI3Kδ Signaling in CD4 T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.
Cancer Res. 2017 Apr 15;77(8):1892-1904. doi: 10.1158/0008-5472.CAN-16-1839. Epub 2017 Jan 20.
4
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E761-E770. doi: 10.1073/pnas.1620433114. Epub 2017 Jan 17.
5
Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal.
Cell Rep. 2016 Dec 20;17(12):3142-3152. doi: 10.1016/j.celrep.2016.11.065.
7
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.
Cell. 2016 Oct 20;167(3):829-842.e13. doi: 10.1016/j.cell.2016.09.031. Epub 2016 Oct 13.
8
Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism.
Science. 2016 Oct 28;354(6311):481-484. doi: 10.1126/science.aaf6284. Epub 2016 Sep 29.
9
Foxp3 and Toll-like receptor signaling balance T cell anabolic metabolism for suppression.
Nat Immunol. 2016 Dec;17(12):1459-1466. doi: 10.1038/ni.3577. Epub 2016 Oct 3.
10
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.
Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验